Evaluate Vantage Homepage
Valneva scores a pyrrhic trial win
The group’s Covid-19 vaccine is on course for UK approval – but the UK doesn’t want it.
Treme climbs a new mountain
Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.
US backs another Covid-19 booster
But a potentially more interesting advisory committee, for Merck and Ridgeback’s molnupiravir, awaits.
Medtech
Medtronic faces a denervation delay
And when the long-awaited trial does finally report it will have to be a smash hit.
Memed seeks partners for bacterial vs viral testing and more
The group’s ambitions are startling, but it will need cash and collaborators to realise them.
Company Events
Springworks seeks cancer win as a prelude to something bigger
The young biotech is well placed to deliver its first pivotal win, but investor focus might lie elsewhere.
Go or no go? UCB bids to make a mark in psoriasis
Chemocentryx and Avadel will also see important FDA regulatory action this month, while Omeros gets another delay.
Crucial clinical events for the smaller players
Data are due in the fourth quarter for Aldeyra, Aeglea and Radius, among other small developers.
Interviews
Boehringer takes a different approach in cystic fibrosis gene therapy
Deals this week with a UK consortium and Oxford Biomedica see the group bet on lentiviral vectors.
Memed seeks partners for bacterial vs viral testing and more
The group’s ambitions are startling, but it will need cash and collaborators to realise them.
Amylyx changes its mind about an early filing
The group hopes phase 2 data will back approval for its amyotrophic lateral sclerosis project AMX0035 after all.